Pay in 4 interest-free payments of $5.92 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
In trials, users experienced decreases in fasting blood sugar and significant reductions in HbA1c, a measurement of long-term blood sugar management
It includes incretin-based therapies where primary clinical positioning centers on weight management and excludes GLP-1 drugs prescribed solely for glycemic control without a labeled obesity indication
Injection Frequency Once daily is the standard protocol
Boston-based Anodyne plans to use proceeds to support the advancement of ANN-101, its once-weekly GLP-1 patch for obesity
Med 335 , 11691175 (1996)
Massey University, Albany, New Zealand: Massey University (2020)
US$ 24.62
US$ 28.27
US$ 29.73
